<?xml version="1.0" encoding="UTF-8"?>
<p id="Par49">The following regimens were administered based on international recommendations [
 <xref ref-type="bibr" rid="CR17">17</xref>]: sofosbuvir (SOF) plus ribavirin (RBV); SOF plus simeprevir (SMV) ± RBV; SOF plus ledipasvir (LDV) ± RBV; SOF plus daclatasvir (DCV) ± RBV; ombitasvir (OBV), paritaprevir/ritonavir (PTV/r) ± dasabuvir(DSV) ± RBV, glecaprevir (GLE) plus pibrentasvir (PIB), grazoprevir (GRZ) plus elbasvir (EBR) ± RBV, SOF plus velpatasvir (VEL) ± RBV. Use of RBV was based on clinical judgement and on the prescribing information document; in particular, an initial dose of 1000 mg or 1200 mg was prescribed according to the patients’ weight (&lt; 75 kg or ≥ 75 kg, respectively).
</p>
